M-PREG : UKCA-certified rule-in test for preeclampsia
®
.png)
Introducing M-PREG – The World’s First and Only Rule-In Test Delivering Fast, Accurate Results for Preeclampsia
®
M-PREG is the world’s first and only UKCA-certified digital diagnostic platform that accurately identifies women at risk of developing preeclampsia – a life-threatening complication of pregnancy. Using a single mid-pregnancy blood test, M-PREG offers clinicians and patients a fast, reliable, and affordable way to detect the disease early. With 93% diagnostic accuracy and no need for kits or machines, M-PREG transforms maternal care by enabling timely intervention, reducing healthcare costs, and saving lives.
View a video demonstration of M-PREG in action below
®
®
®
®
How does M-PREG for Preeclampsia work?
®
Step 1: Order a Routine Blood Test
At 20–30 weeks of pregnancy, the clinician orders a standard maternal blood test measuring key biomarkers already in use (no special kits or equipment needed).
Step 2: Upload Results to M-PREG
®
The clinician (or lab) logs into the secure, cloud-based M-PREG platform and inputs the test values. No physical sample processing, no waiting for lab-specific results.
®
Step 3: Receive Instant Risk Assessment
M-PREG analyses the data instantly and provides a definitive “Rule-In” result with >90% accuracy — guiding clinical decisions within seconds.
®
How is M-PREG for Preeclampsia different?
®
>90% ACCURACY
Clinically validated with high sensitivity and specificity offering unmatched reliability for early intervention.
INSTANT RESULT
Get accurate diagnostic results in seconds — reducing waiting time, anxiety, and unnecessary hospital stays
RULE-IN TEST
Unlike traditional “rule-out” tests, M-PREG definitively confirms preeclampsia risk with a single test.
®
DIAGNOSTIC AND PROGNOSTIC
Not just predictive — M-PREG also tracks patient response to therapy, paving the way for personalised care.
®
NO KITS, NO MACHINE, NO HASSLE
Uses existing biomarker data — no special equipment or lab setup needed. Simply upload results to the digital platform
CLINICIAN & PATIENT FRIENDLY
Designed to integrate seamlessly into existing workflows and accessible for both clinical and future at-home use.
Professor Stephen K. Smith DSc FRCOG FMEDSci
Former Principal of Medicine, Imperial College London
“M-PREG represents a new era in precision obstetrics. For the first time, we can move from reactive care to proactive prevention of preeclampsia—guided by molecular insight and delivered through a clinically practical test. This is exactly the kind of innovation maternal health has been waiting for. I’m glad to be part of this journey—from discovery to diagnostics—as M-PREG changes the future of maternal health.”
®
®
Professor Asif Ahmed PhD
Founder & CEO, MirZyme Therapeutics
"At MirZyme, we believe no woman should die from a preventable complication like preeclampsia. We now understand the molecular pathways that drive this devastating condition—and have translated that knowledge into action. M-PREG is the result of decades of research, now a practical tool for clinicians. This is how we bring science to the bedside—with precision, purpose, and the potential to save millions of lives.”
®
Professor Penśee Wu MBChB MD (Res) FRCOG
Professor of Obstetrics, Keele University; Consultant, NHS Trust
“M-PREG can transform the clinical management of preeclampsia. Its ability to deliver rapid, evidence-based risk stratification through a simple blood test gives clinicians the confidence to make earlier, informed decisions—improving outcomes for both mothers and babies.”
®
Dr Swati Agarwal MBBS MD MRCOG MSc (Oxon)
Maternal-Fetal Medicine Specialist, McMaster University
“Preeclampsia is one of the most challenging and unpredictable conditions in obstetrics. M-PREG offers a clinically validated, early diagnostic tool that allows us to identify at-risk women before symptoms arise—this could fundamentally change how we manage maternal care globally.”
®
Dr Aqil Jaigirdar MD
Founder & CEO, Maternal Aid Association (MAA)
“M-PREG has the potential to radically improve maternal outcomes—especially in low-resource settings where early diagnosis is often missed. At the Maternal Aid Association, we believe innovations like this are not just game-changers—they are life-changers.”
®
What are global experts saying about M-PREG ?
®
Interested in using or partnering on M-PREG ? Let's talk.
®
Whether you're an NHS trust, hospital group, insurer, clinician, diagnostic lab, or government agency, we’d love to hear from you. Please complete the form below and our team will be in touch shortly.
@MirZyme
MirZyme Therapeutics, Birmingham, B7 4BB, UK